menu
    • menu
    [{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dar\u00e9 Bioscience","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Intravaginal","sponsorNew":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1 inhibitor","graph1":"Dermatology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Solaris Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1 inhibitor","graph1":"Dermatology","graph2":"Approved","graph3":"Solaris Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Solaris Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Solaris Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1 inhibitor","graph1":"Dermatology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1 inhibitor","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Ortho Dermatologics \/ Baush Health","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Dermatologics \/ Baush Health"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0.19,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.19,"dosageForm":"","sponsorNew":"Dar\u00e9 Bioscience \/ Dare Bioscience","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Bioscience \/ Dare Bioscience"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0.19,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Bioscience \/ Organon"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Douglas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Douglas Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Bioscience \/ Douglas Pharmaceuticals"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0.19,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Bioscience \/ Organon"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Organon \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Clindamycin Phosphate

    Menu

    Clindamycin Phosphate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Glenmark Pharmaceuticals

                            India arrow
                            BioAsia
                            Not Confirmed

                            Glenmark Pharmaceuticals

                            India arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Glenmark Pharmaceuticals Inc., USA Launches Clindamycin Phosphate Foam, 1%

                            Details : Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent approved by USFDA, to the reference listed drug, Evoclin, for the treatment of acne vulgaris.

                            Product Name : Evoclin-Generic

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            February 13, 2025

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bausch Health

                            Canada arrow
                            BioAsia
                            Not Confirmed

                            Bausch Health

                            Canada arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Health Canada Approves CABTREO™ for Acne Vulgaris in Patients 12 and Older

                            Details : CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel is a prescription medicine indicated for acne vulgaris in patients 12 years of age and older.

                            Product Name : Cabtreo

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 11, 2024

                            Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bausch Health

                            Canada arrow
                            BioAsia
                            Not Confirmed

                            Bausch Health

                            Canada arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CABTREO™ Topical Gel for Acne Now Available in the U.S.

                            Details : CABTREO (clindamycin phosphate, adapalene, benzoyl peroxide) topical gel is a prescription medicine which is now available in US for the topical treatment of acne vulgaris in age 12 years and older.

                            Product Name : Cabtreo

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 30, 2024

                            Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Organon

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Organon

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Daré Bioscience

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Organon’s XACIATO Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis

                            Details : Xaciato (clindamycin phosphate) vaginal gel 2% is a USFDA approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older.

                            Product Name : Xaciato

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 10, 2024

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Daré Bioscience

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bausch Health

                            Canada arrow
                            BioAsia
                            Not Confirmed

                            Bausch Health

                            Canada arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves Cabtreo(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment...

                            Details : Cabtreo (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel which is indicated for the treatment of Acne Vulgaris in patients twelve years of age and older.

                            Product Name : Cabtreo

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 20, 2023

                            Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Daré Bioscience

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Daré Bioscience

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Organon

                            Deal Size : $192.8 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (C...

                            Details : Under the agreement, Daré has the global rights to Xaciato (clindamycin phosphate vaginal gel), an FDA-approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older.

                            Product Name : Xaciato

                            Product Type : Small molecule

                            Upfront Cash : $10.0 million

                            October 16, 2023

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Organon

                            Deal Size : $192.8 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Daré Bioscience

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Daré Bioscience

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Douglas Pharmaceuticals

                            Deal Size : $7.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Daré Bioscience Completes Previously Announced Equity Financing

                            Details : The net proceeds will be used the commercial launch of XACIATO (clindamycin phosphate) vaginal gel, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older.

                            Product Name : Xaciato

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 05, 2023

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Douglas Pharmaceuticals

                            Deal Size : $7.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Daré Bioscience

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Daré Bioscience

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phospha...

                            Details : Xaciato (clindamycin phosphate vaginal gel) inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome, FDA-approved treatment for females 12 and older with bacterial vaginosis.

                            Product Name : Xaciato

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 05, 2023

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

                            Details : Esmolol hydrochloride in sodium chloride injection is indicated for tachycardia. Company launched 8 new generic products, including clindamycin phosphate gel 1%, ipratropium bromide nasal sprays, and prednisolone sodium phosphate oral solution.

                            Product Name : Clindamycin Phosphate-Generic

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 20, 2022

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Daré Bioscience

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Daré Bioscience

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Organon

                            Deal Size : $192.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Dare Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO (clindamyc...

                            Details : Under the agreement, Organon licensed global rights to XACIATO (clindamycin phosphate vaginal gel, 2%), an FDA-approved medication for the treatment of bacterial vaginosis in females 12 years of age and older.

                            Product Name : Xaciato

                            Product Type : Small molecule

                            Upfront Cash : $10.0 million

                            June 30, 2022

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Organon

                            Deal Size : $192.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth